Edition:
India

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

142.98USD
6 Jul 2020
Change (% chg)

$2.01 (+1.43%)
Prev Close
$140.97
Open
$142.17
Day's High
$143.76
Day's Low
$141.91
Volume
1,763,859
Avg. Vol
3,129,868
52-wk High
$157.00
52-wk Low
$109.17

Latest Key Developments (Source: Significant Developments)

Janssen Announces Discontinuation Of Phase 3 Lotus Study Evaluating Ustekinumab In Systemic Lupus Erythematosus
Friday, 26 Jun 2020 

June 26 (Reuters) - Johnson & Johnson ::JANSSEN ANNOUNCES DISCONTINUATION OF PHASE 3 LOTUS STUDY EVALUATING USTEKINUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS.JANSSEN PHARMACEUTICAL - TO DISCONTINUE PHASE 3 LOTUS STUDY OF STELARA IN SYSTEMIC LUPUS ERYTHEMATOSUS DUE TO LACK OF EFFICACY IN SLE.JANSSEN PHARMACEUTICAL - DECISION TO DISCONTINUE LOTUS STUDY DOES NOT IMPACT ANY OTHER ONGOING STUDIES WITH USTEKINUMAB OR CURRENT INDICATIONS.JANSSEN PHARMACEUTICAL - INTERIM SAFETY FINDINGS WERE CONSISTENT WITH KNOWN SAFETY PROFILE OF STELARA, AND NO NEW SAFETY SIGNALS WERE IDENTIFIED.  Full Article

Halozyme To Receive $10 Million Milestone Payment From Janssen
Monday, 22 Jun 2020 

June 22 (Reuters) - Halozyme Therapeutics Inc ::HALOZYME TO RECEIVE $10 MILLION MILESTONE PAYMENT FROM JANSSEN.HALOZYME THERAPEUTICS -WILL RECEIVE $10 MILLION MILESTONE PAYMENT FROM JANSSEN BIOTECH TRIGGERED UNDER COLLABORATION & LICENSE AGREEMENT BETWEEN TWO COS.  Full Article

Janssen Announced New Long-Term Plaque Psoriasis Data For Tremfya
Monday, 15 Jun 2020 

June 15 (Reuters) - JANSSEN::JANSSEN - ANNOUNCED NEW LONG-TERM PLAQUE PSORIASIS DATA FOR TREMFYA.JANSSEN - NEW PHASE 3 DATA FOR TREMFYA SHOW CONSISTENT, HIGH LEVELS OF SKIN CLEARANCE THROUGH 4 YRS IN ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS.JANSSEN - SAFETY PROFILES OBSERVED FOR GUSELKUMAB AND ADALIMUMAB IN VOYAGE 2 WERE CONSISTENT WITH KNOWN SAFETY PROFILES.JANSSEN - DATA SHOWS HIGHER PROPORTION OF PATIENTS TREATED WITH GUSELKUMAB REPORTED SYMPTOM-FREE & SIGN-FREE STATUS THROUGH 48 WEEKS VERSUS ADALIMUMAB.JANSSEN - NO NEW SAFETY SIGNALS WERE IDENTIFIED AT FOUR YEARS IN PRESENTED ANALYSES OF TREMFYA.  Full Article

Bavarian Nordic To Manufacture Additional Ebola Vaccines For Janssen
Friday, 12 Jun 2020 

June 12 (Reuters) - Bavarian Nordic A/S ::REG-BAVARIAN NORDIC TO MANUFACTURE ADDITIONAL EBOLA VACCINES FOR JANSSEN.BAVARIAN NORDIC TO MANUFACTURE ADDITIONAL EBOLA VACCINES FOR JANSSEN.ENTERED NEW SUPPLY CONTRACT WITH JANSSEN VACCINES & PREVENTION VALUED AT USD 13.9 MLN.MANUFACTURING OF VACCINES WILL BE INITIATED IN 2020, SUPPLY AND INVOICING WILL NOT OCCUR UNTIL 2021.WILL MANUFACTURE, DELIVER BULK DRUG SUBSTANCE OF MVA-BN FILO VACCINE, WHICH JANSSEN HAS LICENSED AS PART OF EBOLA VACCINE REGIMEN.  Full Article

Johnson & Johnson Announces Acceleration Of Its Covid-19 Vaccine Candidate
Wednesday, 10 Jun 2020 

June 10 (Reuters) - Johnson & Johnson ::JOHNSON & JOHNSON ANNOUNCES ACCELERATION OF ITS COVID-19 VACCINE CANDIDATE; PHASE 1/2A CLINICAL TRIAL TO BEGIN IN SECOND HALF OF JULY.J&J - PHASE 1/2A STUDY OF INVESTIGATIONAL SARS-COV-2 VACCINE, AD26.COV2-S, WILL TAKE PLACE IN U.S. AND BELGIUM.J&J - PHASE 1/2A FIRST-IN-HUMAN CLINICAL TRIAL OF AD26.COV2-S IS NOW EXPECTED TO COMMENCE IN SECOND HALF OF JULY.J&J - IN DISCUSSIONS WITH NIAID WITH OBJECTIVE TO START PHASE 3 AD26.COV2-S, RECOMBINANT, CLINICAL TRIAL AHEAD OF ITS ORIGINAL SCHEDULE.J&J - IN DISCUSSIONS TO START PHASE 3 SARS-COV-2 VACCINE TRIAL AHEAD OF SCHEDULE, PENDING PHASE 1 STUDIES OUTCOME, REGULATOR APPROVAL.  Full Article

European Commission Grants Marketing Authorisation For Darzalex(Daratumumab) Subcutaneous Formulation For All Currently Approved Daratumumab Intravenous Formulation Indications
Thursday, 4 Jun 2020 

June 4 (Reuters) - Janssen Pharmaceutical::EUROPEAN COMMISSION GRANTS MARKETING AUTHORISATION FOR DARZALEX(DARATUMUMAB) SUBCUTANEOUS FORMULATION FOR ALL CURRENTLY APPROVED DARATUMUMAB INTRAVENOUS FORMULATION INDICATIONS.JANSSEN PHARMACEUTICAL - APPROVAL IS SUPPORTED BY DATA FROM PHASE 2 PLEIADES (MMY2040 ) AND PHASE 3 COLUMBA (MMY3012 ) STUDIES..  Full Article

Johnson & Johnson Receives Positive CHMP Opinion For Janssen's Investigational Preventive Ebola Vaccine Regimen
Friday, 29 May 2020 

May 29 (Reuters) - Johnson & Johnson ::JOHNSON & JOHNSON RECEIVES POSITIVE CHMP OPINION FOR JANSSEN’S INVESTIGATIONAL PREVENTIVE EBOLA VACCINE REGIMEN.J&J - DISCUSSIONS WITH FDA ONGOING TO DEFINE REQUIRED DATA SET FOR FILING JANSSEN'S EBOLA VACCINE REGIMEN UNDER FDA'S ANIMAL RULE LICENSURE PATHWAY.  Full Article

Genmab Says Positive Topline Results In Phase III Andromeda Study Of Daratumumab In Light-Chain (AL) Amyloidosis
Thursday, 28 May 2020 

May 28 (Reuters) - Genmab A/S ::REG-GENMAB ANNOUNCES POSITIVE TOPLINE RESULTS IN PHASE III ANDROMEDA STUDY OF DARATUMUMAB IN LIGHT-CHAIN (AL) AMYLOIDOSIS.GENMAB - PHASE III ANDROMEDA STUDY OF DARATUMUMAB IN LIGHT-CHAIN (AL) AMYLOIDOSIS MET PRIMARY ENDPOINT OF PATIENTS WITH HEMATOLOGIC COMPLETE RESPONSE.GENMAB - STUDY, CONDUCTED BY JANSSEN BIOTECH MET PRIMARY ENDPOINT OF PERCENTAGE OF PATIENTS WITH HEMATOLOGIC COMPLETE RESPONSE.GENMAB - JANSSEN WILL DISCUSS DATA WITH HEALTH AUTHORITIES TO PREPARE FOR REGULATORY FILINGS.  Full Article

Johnson & Johnson Consumer Health Announces Discontinuation Of Talc-Based Johnson's Baby Powder In U.S. & Canada
Wednesday, 20 May 2020 

May 19 (Reuters) - Johnson & Johnson Consumer Health::JOHNSON & JOHNSON CONSUMER HEALTH ANNOUNCES DISCONTINUATION OF TALC-BASED JOHNSON’S BABY POWDER IN U.S. AND CANADA.JOHNSON & JOHNSON CONSUMER HEALTH - IN MARCH, JOHNSON & JOHNSON CONSUMER HEALTH STOPPED SHIPPING HUNDREDS OF ITEMS IN THE U.S. & CANADA.J&J CONSUMER HEALTH - DECIDED TO PERMANENTLY DISCONTINUE ABOUT 100 SKUS FROM THE MARCH ASSESSMENT, AS WELL AS TALC-BASED JOHNSON’S BABY POWDER.J&J CONSUMER HEALTH - JOHNSON’S BABY POWDER REPRESENTS ABOUT 0.5% OF THE TOTAL U.S. CONSUMER HEALTH BUSINESS.JOHNSON & JOHNSON CONSUMER HEALTH - DEMAND FOR TALC-BASED JOHNSON’S BABY POWDER IN NORTH AMERICA HAS BEEN DECLINING.JOHNSON & JOHNSON CONSUMER HEALTH - WILL WIND DOWN COMMERCIALIZATION OF TALC-BASED JOHNSON’S BABY POWDER IN THE U.S. AND CANADA IN COMING MONTHS.J&J CONSUMER HEALTH - CORNSTARCH-BASED JOHNSON’S BABY POWDER WILL REMAIN AVAILABLE IN NORTH AMERICA.J&J CONSUMER HEALTH - TALC-BASED AND CORNSTARCH-BASED JOHNSON’S BABY POWDER, WILL CONTINUE TO BE SOLD IN OTHER MARKETS AROUND THE WORLD.J&J CONSUMER HEALTH - WILL CONTINUE TO DEFEND TALC-BASED JOHNSON’S BABY POWDER IN THE COURTROOM.  Full Article

Johnson & Johnson discontinuing talc-based Johnson’s baby powder in U.S. and Canada
Wednesday, 20 May 2020 

May 19 (Reuters) - Johnson & Johnson ::Says discontinuing talc-based Johnson’s baby powder in U.S. and Canada.Says demand for talc-based Johnson’s baby powder in North America has been declining.Says decline in demand for talc-based baby powder due to changes in consumer habits, "misinformation around the safety of the product".Says remains steadfastly confident in the safety of talc-based Johnson’s baby powder.  Full Article

FACTBOX-Latest on the worldwide spread of the coronavirus

July 7 The World Health Organization is reviewing a report urging it to update guidance on the novel coronavirus after more than 200 scientists, in a letter to the health agency, outlined evidence the virus can spread in tiny airborne particles.